16 de octubre de 2019
24 de septiembre de 2009

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects (y 2)


A. Pg. 20, col. 1, par. 1
B. Pg. 23, col. 1, par. 3
C. Pg. 22, col. 1, par. 2 and 3
D. Pg. 15, col. 1, par. 1 and 2
E. Pg. 15, col. 2, par. 2 (Rustin response)
F. Pg. 15, col. 1, par. 3

(3) Morphotek, Inc. Clinical Trial Protocol: MORAb-003-002, Morphotek, Inc., "A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse." Revised April 9, 2007.

A. Pg. 8, col. 1, par. 6

(4) National Cancer Institute. CA-125. Available at http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=46490. Accessed September 10, 2009.

A. Pg. 1, col. 1., par. 1

(5) National Cancer Institute. Ovarian Cancer. Available at: http://www.cancer.gov/cancer_information/cancer_type/ovarian.... Accessed September 10, 2009.

[TAB]

A. Pg. 1, col. 1, par. 1

B. Pg. 1, col. 1, par. 2

[FTAB]

(6) American Cancer Society. Cancer Statistics 2009 Slide. Slide 2. Available at: http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Sta... entation.asp. Accessed September 10, 2009.

A. Pg. 2, col. 2, par. 1

(7) National Cancer Institute. Ovarian Cancer Symptoms. Available at: http://www.cancer.gov/cancertopics/wyntk/ovary/page5. Accessed September 11, 2009.

A. Pg. 1, col. 1., par 1 and 4

(8) Cancer Intelligence, sponsored by Professor Gordon McVie, former Chief Executive of The Cancer Research Campaign and joint Chief Executive of the new charity Cancer Research UK and current consultant at the European Institute of Oncology. Ovarian Cancer. Available at: http://www.ecancermedia.com/Ovarian_Cancer_Factsheet.aspx. Accessed September 11, 2009.

A. Pg. 4, col. 1, par. 10

(9) Morphotek, Inc. Clinical Trial Protocol: MORAb-003-004, Morphotek, Inc., "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse." Revised February 2, 2009.

A. Pg. 2, col. 1., par 2

Nonpro-EU2004

Judee Shuler, Eisai Inc., +1-201-746-2241, judee_shuler@eisai.com; or Robert Laverty, Eisai Corporation of North America, +1-201-746-2265, robert_laverty@eisai.com


A. Pg. 1, col. 1, par. 1
B. Pg. 1, col. 1, par. 2

(6) American Cancer Society. Cancer Statistics 2009 Slide. Slide 2. Available at: http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Sta... entation.asp. Accessed September 10, 2009.

A. Pg. 2, col. 2, par. 1

(7) National Cancer Institute. Ovarian Cancer Symptoms. Available at: http://www.cancer.gov/cancertopics/wyntk/ovary/page5. Accessed September 11, 2009.

A. Pg. 1, col. 1., par 1 and 4

(8) Cancer Intelligence, sponsored by Professor Gordon McVie, former Chief Executive of The Cancer Research Campaign and joint Chief Executive of the new charity Cancer Research UK and current consultant at the European Institute of Oncology. Ovarian Cancer. Available at: http://www.ecancermedia.com/Ovarian_Cancer_Factsheet.aspx. Accessed September 11, 2009.

A. Pg. 4, col. 1, par. 10

(9) Morphotek, Inc. Clinical Trial Protocol: MORAb-003-004, Morphotek, Inc., "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse." Revised February 2, 2009.

A. Pg. 2, col. 1., par 2

Nonpro-EU2004

Judee Shuler, Eisai Inc., +1-201-746-2241, judee_shuler@eisai.com; or Robert Laverty, Eisai Corporation of North America, +1-201-746-2265, robert_laverty@eisai.com